Nigel Fleming insider trades: Impax Laboratories (IPXL) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Nigel reports to the SEC
Open-market buys and sales
18 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 31, 2015 | IPXL | ↓ Sell | 29,166 | $41.02 | $1.2M | Direct | Sep 1, 2015 (1d) |
| May 16, 2014 | IPXL | ↓ Sell | 1,900 | $25.72 | $49K | Direct | May 19, 2014 (3d) |
| May 12, 2014 | IPXL | ↓ Sell | 1,333 | $26.58 | $35K | Direct | May 12, 2014 (0d) |
| May 6, 2014 | IPXL | ↓ Sell | 4,000 | $26.34 | $105K | Direct | May 8, 2014 (2d) |
| Apr 8, 2013 | IPXL | ↓ Sell | 6,000 | $16.20 | $97K | Direct | Apr 10, 2013 (2d) |
| Apr 1, 2013 | IPXL | ↓ Sell | 6,000 | $15.31 | $92K | Direct | Apr 2, 2013 (1d) |
| Mar 25, 2013 | IPXL | ↓ Sell | 6,000 | $15.60 | $94K | Direct | Mar 26, 2013 (1d) |
| Aug 27, 2012 | IPXL | ↓ Sell | 6,000 | $23.92 | $144K | Direct | Aug 28, 2012 (1d) |
| Aug 20, 2012 | IPXL | ↓ Sell | 6,000 | $23.99 | $144K | Direct | Aug 22, 2012 (2d) |
| Aug 13, 2012 | IPXL | ↓ Sell | 6,000 | $23.91 | $143K | Direct | Aug 13, 2012 (0d) |
| Aug 6, 2012 | IPXL | ↓ Sell | 6,667 | $23.92 | $159K | Direct | Aug 6, 2012 (0d) |
| Sep 1, 2011 | IPXL | ↓ Sell | 14,640 | $19.04 | $279K | Direct | Sep 6, 2011 (5d) |
| Jun 7, 2011 | IPXL | ↓ Sell | 13,334 | $23.45 | $313K | Direct | Jun 9, 2011 (2d) |
| Dec 9, 2010 | IPXL | ↓ Sell | 8,500 | $18.70 | $159K | Direct | Dec 13, 2010 (4d) |
| Aug 10, 2010 | IPXL | ↓ Sell | 7,500 | $16.83 | $126K | Direct | Aug 12, 2010 (2d) |
| Jun 4, 2010 | IPXL | ↓ Sell | 1,360 | $20.37 | $28K | Direct | Jun 8, 2010 (4d) |
| May 17, 2010 | IPXL | ↓ Sell | 8,000 | $19.50 | $156K | Direct | May 19, 2010 (2d) |
| Aug 14, 2009 | IPXL | ↓ Sell | 4,000 | $7.69 | $31K | Direct | Aug 18, 2009 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Nigel Fleming's insider trades
Nigel Fleming is a director at Impax Laboratories (IPXL). Since Aug 14, 2009, Nigel has reported no open-market purchases and 18 sales worth $3.4M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include option exercises (11 filings), grants and awards (7 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IPXL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.